Status:
COMPLETED
Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Alzheimer Disease
Healthy
Eligibility:
MALE
20+ years
Phase:
PHASE1
Brief Summary
This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of PAZ-417 after administration of ascending single oral doses to healthy young Japanese male and h...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Men aged 20 to 45 years inclusive (healthy young male subjects) and ≥65 years inclusive (healthy elderly male subjects)
- Nonsmoker or smoker of fewer than 10 cigarettes per day.
- Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).
- Exclusion Criteria
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- Subjects who are identified as being at risk for hypercoagulability
- Use of any investigational or prescription drug within 30 days before test article administration
Exclusion
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00684710
Start Date
April 1 2008
End Date
August 1 2008
Last Update
January 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kitashinagawa, Shinagawa-ku, Tokyo, Japan, 141-0001